Anticancer research
-
Anticancer research · Jul 2010
Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
In human epidermal growth factor 2 (HER-2)-positive advanced breast cancer, taxanes plus trastuzumab are among the most widely applied options in the first-line setting. The addition of capecitabine to docetaxel significantly improves overall survival in anthracycline-pretreated metastatic breast cancer. We evaluated the efficacy and tolerability of trastuzumab plus capecitabine and docetaxel regimen as first-line therapy. ⋯ These data confirm that the combination of trastuzumab plus capecitabine and docetaxel is highly active in patients with HER-2-overexpressing anthracycline-pretreated breast cancer, offering a significant survival benefit and is well tolerated.
-
Anticancer research · May 2010
ReviewEvidence-based complementary oncology: innovative approaches to optimise standard therapy strategies.
Cancer diseases demand diagnostic and therapeutic measures with proven quality, safety and efficacy. Bases for evaluation of new clinical and therapeutic measures are clinical studies representing level I (randomised controlled trials [RCTs]) or level II (epidemiological cohort studies), in accordance with recommendations of the Centre for Evidence-Based Medicine, University of Oxford, UK. ⋯ These therapies have all proven their potency to destroy cancer and their curative feasibility. This review provides an overview of some of the complementary therapies that are also recommended to support and optimise the standard evidence based cancer treatments.
-
Curcumin (diferuloylmethane) is a commonly used spice and nutritional supplement that has demonstrated potential anti-tumor and anti-inflammatory activity. There is limited information regarding curcumin metabolism and the potential for drug-drug interactions. The objective of this study was to characterize the hepatic metabolism of synthetic curcumin used in the liposomal curcumin formulation. ⋯ There is low potential for CYP450 mediated drug interactions at physiologic serum concentrations of liposomal curcumin. Based on preliminary data, liposomal curcumin will not interact with other chemotherapy agents that are metabolized and/or eliminated via the primary drug metabolizing CYP450 pathways.
-
Anticancer research · Mar 2010
Chemopreventive effects of honokiol on UVB-induced skin cancer development.
Skin cancer is the most prevalent of all cancer types and its incidence is expected to increase substantially. Chemoprevention involves the administration of chemical agents to prevent initiation, promotion and/or progression that occurs during neoplastic development. Honokiol, a plant lignan isolated from bark and seed cones of Magnolia officinalis, has been shown to have chemopreventive effects on chemically induced skin cancer development. ⋯ Pretreatment with honokiol, at concentrations in micrograms per application compared with milligram applications of other potential chemopreventive agents, prevents UVB-induced skin cancer development, possibly by activating proapoptotic proteins through both intrinsic and extrinsic pathways.
-
Anticancer research · Feb 2010
The relationship between obesity and cancer mortality in type 2 diabetes: a ten-year follow-up study (ZODIAC-21).
Patients with type 2 diabetes mellitus (T2DM) as well as patients with obesity have increased cancer mortality. In a previous paper we suggested that there was a trend for decreased mortality in obese individuals with T2DM. The aim of the new analyses was to investigate the same relationship after increasing our sample size and extending our follow-up period. ⋯ The trend towards an inverse relationship between obesity and cancer mortality as reported previously disappeared after increasing sample size and follow-up to 9.6 years.